Clinical trial NCT00583713: An Open Label Study to Assess the Effect of BLI800 on Safety and Clinical Chemistry Parameters
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Colonoscopy
Bowel Preparation
Lead sponsor: Braintree Laboratories
Sponsor class: INDUSTRY
First posted: 2007-12-31
Enrollment: 18
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To evaluate and compare the effects on safety measures and clinical chemistry after BLI800 in two groups of patients and one group of healthy controls. The patient groups will be those with mild or moderate hepatic impairment or moderate renal disease.


Eligibility criteria: Inclusion Criteria:

* Are male or female adults who are:

  * With Child-Pugh Hepatic Dysfunction Stage A or B, or
  * With Moderate Renal Disease or
  * Healthy subjects matched to those who are enrolled in this study
* Subjects who are considered to have only clinically non-significant conditions, as judged by the Principal Investigator and based on physical examination, laboratory profiles, medical history and ECG.
* Female subjects who are not surgically sterile (i.e., having had a hysterectomy, bilateral oophorectomy or tubal ligation) or who are not at least 2 years naturally postmenopausal must agree to use an acceptable form of contraception.
* Provide voluntary consent in writing to participate in this study.

Exclusion Criteria:

* Subjects with known or suspected ileus, severe ulcerative colitis, gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis, or megacolon.
* Subjects with impaired consciousness that predisposes them to pulmonary aspiration.
* Subjects who, in the opinion of the Principal Investigator, have uncontrolled clinically significant pre-existing electrolyte disturbances, based on the Screening visit laboratory results.
* Subjects with present or prior NYHA Functional Classification grade III or IV congestive heart failure.
* Subjects who are pregnant or lactating, or intending to become pregnant during the study.
* Subjects of childbearing potential who refuse a pregnancy test.
* Subjects who have participated in an investigational clinical, surgical, drug, or device study within the past 30 days.
* Subjects with a history of allergic or adverse response to any BLI-800 component.
* Subjects who donated more than one pint of blood within 30 days prior to the study.
* Subjects who donated plasma within 7 days prior to the study.
* Subjects who had an abnormal diet or substantial changes in eating habits within 30 days prior to the start of the study.
* Subjects who have had a bowel cleansing procedure within the past month or who have taken a laxative within the 5 days (120 hours) prior to dosing or who require a laxative every day.
* Subjects who, in the opinion of the Investigator, should not be included in the study for any reason, including inability to follow study procedures.

Primary outcomes:
measure: Maximum Observed Concentration (Cmax)
timeFrame: 1 day
measure: Time to Maximum Concentration
timeFrame: 1 day
measure: Terminal Half-life
timeFrame: 1 day
measure: Area Under the Curve for the 24-hour Dosing Interval
timeFrame: 1 day
measure: Elimination Rate Constant
timeFrame: 1 day
Secondary outcomes:
measure: Urinary Sulfate Concentration
timeFrame: pre-dose to 6 days post-dose
Other outcomes:
Locations:
city: Minneapolis
country: United States
state: Minnesota
Study officials:
affiliation: Braintree Laboratories, Inc.
name: Russell Pelham, Ph.D.
role: STUDY_DIRECTOR
References: